In the Phase III VISIONARY study, sibeprenlimab, an investigational monoclonal antibody, showed a 51.2% reduction in ...

As CIDP moves toward targeted therapies and patient-friendly regimens, the market is primed for disruption—offering a fresh ...

Results from the PATH study indicate that subcutaneous immunoglobulin is efficacious and well tolerated for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (CIDP).

Subcutaneous (SCIG) and intravenous immunoglobulin (IVIG) replacement are both used to prevent infections in patients with secondary immunodeficiency (SID). Compared with IVIG, SCIG has fewer systemic ...

Finally, subcutaneous immunoglobulin (SCIG), an immunoglobulin treatment administered under the skin, is an alternative treatment you could consider. SCIG can be administered at home and uses a ...

Also, there are advancements in delivery systems such as subcutaneous immunoglobulin (SCIG), complement IVIG therapies and cater to patient preferences. Apart from this, IVIG market should definitely ...

The agreement is intended for KORU Medical to develop and seek regulatory clearance for a next-generation subcutaneous immunoglobulin (SCIg) therapy infusion system for use with a commercialized ...

HYQVIA ® is the first plasma-derived therapy for subcutaneous injection in Japan that consists of a combination of one vial of Immunoglobulin 10% and one vial of Recombinant Human Hyaluronidase ...

The approval marks availability of the first and only facilitated subcutaneous immunoglobulin (fSCIG) therapy as a treatment option for appropriate patients in Japan. HYQVIA is the first plasma ...

"Moving to IVIG before the infections start makes much more sense." Banerjee also commented that, in general, "the myeloma field has been moving from IV treatments to subcutaneous treatments to ...

The randomized control trial will assess whether Hizentra, a subcutaneous immunoglobulin treatment, can alleviate symptoms of postural orthostatic tachycardia syndrome, or POTS — a disorder of ...